Committee Staff: Liz Pettengill (410) 727-2820, x41
Chair: This committee is chaired by David Block, MD, MBA, CEO of Gliknik.
Dr. Block is a serial entrepreneur and the founder of Ruxton Pharmaceuticals and Gliknik. He has been in the bioscience industry for 17 years, 12 of which were in a series of commercial positions at DuPont Merck and DuPont Pharmaceuticals, including sales management, licensing, portfolio planning, market development and product launch.
He was executive vice president of international operations at the time of the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb. From 2002-04, Dr. Block was the COO of Celera Genomics.
Members: Membership in the Bioscience Committee is by invitation only. This is to keep a constant ratio of largely company CEOs and service providers. Members include: Scott Allocco, CEO, BioMarker Strategies; Jonathan Cohen, CEO, 20/20 GeneSystems, Inc.; Eddy Agbo, CEO, Fyodor Biotechnologies, Inc.; Blake Paterson, CEO, Cerecor, Inc.; and Robert Estey, CEO, MastixMedica, Inc.
What does the committee do:
What has the committee done:
What is the value in joining: The Bioscience Committee is recognized as an effective advocacy and informational resource. Through this committee, the GBC partners with other bioscience industry groups to make sure the industry is always well represented. The committee draws its strength from the input of its members and from the strength of its voice, which is directly connected to the number and caliber of companies that join. This is also an excellent way to meet other members of the bioscience business community and to interface with our research universities.
9/30/13 - Gliknik Inc., a privately-held biopharmaceutical company, announced Sept. 30 it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. for GL-2045, Gliknik's recombinant stradomer, a drug candidate designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in a broad range of preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used. (Read more)
4/16/13 - Baltimore-based Graybug and CEO Christy Wyskiel of our bioscience committee have won the highly competitive Invest Maryland Challenge award of $100,000 in the category of the life sciences. Graybug is developing drugs to more effectively treat eye diseases, such as age-related macular degeneration. There were more than 260 companies nationwide that entered the competition. The announcement was made Monday night at a ceremony at the Maryland Institute College of Art.
4/12/13 - The Governor's budget that passed also included a grant to the BioTechnical Institute of Maryland for $250,000. Congratulations to Kathleen Weiss for her unflagging efforts to train the bio workforce.
4/12/13 - Bioscience committee member BD Diagnostics received U.S. Food and Drug Administration clearance to market the BD MAX Cdiff Assay in the United States. The assay, already in use in Europe, is designed to rapidly and accurately detect the toxin B Gene, which has been shown to cause disease in patients suspected of Clostridium difficile infection. Clostridium difficile is a bacteria that causes a gut infection that causes diarrhea and other serious intestinal conditions such as colitis, and is a growing threat in hospitals, nursing homes and other health care settings.
4/9/13 -The operating budget passed by Maryland lawmakers includes $10 million in available tax credits for biotechnology investment, a $2 million increase from the current fiscal year. Also passed was GBC-supported legislation that expands tax-credit eligibility for investors in Maryland biotechnology companies.
The R&D tax credit was increased from $6 million to $8 million and includes the provision for small businesses to receive a refundable tax credit as supported by the GBC.
4/2/13 - One of our committee members, Christy Wyskiel, CEO of Graybug, has been named as one of nine finalists in the Invest Maryland Challenge. This designation makes Graybug eligible for a $100,000 grant from the state of Maryland. Finalists were chosen from an initial field of 260 applicant companies in three fields.